Key result
Ginseng formulations show potential adjunctive benefit in heart failure, but large clinical trials remain lacking.
Answers are grounded in this paper and cite their sources.
Heart failure is a major medical and economic burden throughout the world. Although various treatment options are available to treat heart failure, death rates in both men and women remain high. Potential adjunctive therapies may lie with use of herbal medications, many of which possess potent pharmacological properties. Among the most widely studied is ginseng, a member of the genus Panax that is grown in many parts of the world and that has been used as a medical treatment for a variety of conditions for thousands of years, particularly in Asian societies. There are a number of ginseng species, each possessing distinct pharmacological effects due primarily to differences in their bioactive components including saponin ginsenosides and polysaccharides. While experimental evidence for salutary effects of ginseng on heart failure is robust, clinical evidence is less so, primarily due to a paucity of large-scale well-controlled clinical trials. However, there is evidence from small trials that ginseng-containing Chinese medications such as Shenmai can offer benefit when administered as adjunctive therapy to heart failure patients. Substantial additional studies are required, particularly in the clinical arena, to provide evidence for a favourable effect of ginseng in heart failure patients.
No takes yet. Share an insight, caveat, or question.
Karmazyn et al. (2017) conducted a review in Cardiac hypertrophy and heart failure. Ginseng, ginsenosides, and ginseng-related products (including Shenmai) was evaluated. Ginseng and ginseng-containing medications such as Shenmai show robust experimental evidence and potential adjunctive clinical benefit in heart failure, though large-scale clinical trials are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: